📊 SNTI Key Takeaways
Is Senti Biosciences, Inc. (SNTI) a Good Investment?
Senti Biosciences is a pre-revenue biotech company with severe cash burn and critically limited runway. Operating losses of $68.8M against only $22K in revenue, combined with $43.4M in annual operating cash outflows against $16.4M in cash reserves, indicates insolvency risk within 4-5 months without additional financing. The company exhibits classic early-stage biotech risk with no demonstrated path to profitability.
Why Buy Senti Biosciences, Inc. Stock? SNTI Key Strengths
- Zero long-term debt reduces financial leverage risk
- Current ratio of 1.67x indicates adequate short-term liquidity position
- Biological products sector offers high growth potential if pipeline succeeds
SNTI Stock Risks: Senti Biosciences, Inc. Investment Risks
- Critical cash runway of approximately 4-5 months at current $43.4M annual burn rate
- Minimal revenue ($22K) with massive operating losses indicates no near-term commercialization
- Stockholders equity of only $5.6M provides minimal buffer; liabilities of $45.6M threaten equity value
- Will require dilutive equity financing to survive, destroying shareholder value
- Early-stage biotech with high probability of clinical/commercial failure
Key Metrics to Watch
- Monthly cash burn rate and cash runway remaining
- Financing announcements and dilution impact
- Clinical trial progress and pipeline advancement milestones
Senti Biosciences, Inc. (SNTI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Senti Biosciences, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
SNTI Profit Margin, ROE & Profitability Analysis
SNTI vs Healthcare Sector: How Senti Biosciences, Inc. Compares
How Senti Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Senti Biosciences, Inc. Stock Overvalued? SNTI Valuation Analysis 2026
Based on fundamental analysis, Senti Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Senti Biosciences, Inc. Balance Sheet: SNTI Debt, Cash & Liquidity
SNTI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Senti Biosciences, Inc.'s revenue has declined by 99% over the 5-year period, indicating business contraction. The most recent EPS of $-12.03 indicates the company is currently unprofitable.
SNTI Revenue Growth, EPS Growth & YoY Performance
SNTI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$11.2M | $-3.36 |
| Q2 2024 | N/A | -$11.2M | $-2.45 |
| Q1 2024 | N/A | -$12.1M | $-0.26 |
| Q3 2023 | $255.0K | -$11.6M | $-0.34 |
| Q2 2023 | $687.0K | -$11.6M | $-0.42 |
| Q1 2023 | $854.0K | -$11.8M | $-0.42 |
| Q3 2022 | $926.0K | -$11.4M | $-0.38 |
| Q2 2022 | $778.0K | -$11.6M | $-0.86 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Senti Biosciences, Inc. Dividends, Buybacks & Capital Allocation
SNTI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Senti Biosciences, Inc. (CIK: 0001854270)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SNTI
What is the AI rating for SNTI?
Senti Biosciences, Inc. (SNTI) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SNTI's key strengths?
Claude: Zero long-term debt reduces financial leverage risk. Current ratio of 1.67x indicates adequate short-term liquidity position.
What are the risks of investing in SNTI?
Claude: Critical cash runway of approximately 4-5 months at current $43.4M annual burn rate. Minimal revenue ($22K) with massive operating losses indicates no near-term commercialization.
What is SNTI's revenue and growth?
Senti Biosciences, Inc. reported revenue of $22.0K.
Does SNTI pay dividends?
Senti Biosciences, Inc. does not currently pay dividends.
Where can I find SNTI SEC filings?
Official SEC filings for Senti Biosciences, Inc. (CIK: 0001854270) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SNTI's EPS?
Senti Biosciences, Inc. has a diluted EPS of $-2.73.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SNTI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Senti Biosciences, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SNTI stock overvalued or undervalued?
Valuation metrics for SNTI: ROE of -1,099.3% (sector avg: 15%), net margin of -279,263.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SNTI stock in 2026?
Our dual AI analysis gives Senti Biosciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SNTI's free cash flow?
Senti Biosciences, Inc.'s operating cash flow is $-43.4M, with capital expenditures of $196.0K. FCF margin is -198,363.6%.
How does SNTI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -279,263.6% (avg: 12%), ROE -1,099.3% (avg: 15%), current ratio 1.67 (avg: 2).